Hukumar Abinci da Magunguna ta Amurka ta amince da AbbVie Inc da likitan likitocin Danish Genmab domin maganin kansar jini na manya waɗanda suka karɓi aƙalla layin jiyya guda biyu.
Maganin, epcoritamab, da za a sayar a ƙarƙashin sunan Epkinly an ƙirƙira shi ne don kula da wani nau’in lymphoma mai girma na B-cell, ciwon daji da ke farawa a cikin fararen jini.
Epcoritamab na cikin nau’in magungunan da ake kira bispecific antibodies waɗanda ke amfani da hadaddun sinadarai na warkewa tare da yiwuwar shigar da ƙwayoyin rigakafi na jiki da kan kai hari kan ƙwayoyin cutar kansa.
Amincewar ta sa epcoritamab ya zama irinshi na farkon samun ƙimar FDA game da cutar wacce ke da kusan sabbin maganganu 150,000 kowace shekara a duniya.
FDA ta sake duba mai yin magungunan Roche’s glofitamab don amfani da shi a cikin rukunin marasa lafiya iri ɗaya.
Amincewar ta faɗaɗa bututun samfurin Abbvie yayin da yake neman ragewa zuwa tallace-tallace daga sabon gasa don maganin cututtukan.
AbbVie da Genmab ne ke haɓaka maganin a matsayin wani ɓangare na yarjejeniyar dala miliyan 750 da kamfanonin suka yi a cikin 2020 don haɓakawa tare da tallata uku daga cikin samfuran rigakafin cutar kansa na Genmab.
A karkashin yarjejeniyar, kamfanonin za su raba nauyin kasuwanci a cikin Amurka da Japan, tare da AbbVie da ke da alhakin ci gaba da kasuwancin duniya.
L.N
Comments are closed.